In the overall patient population, median rwOS for patients with ECOG PS 0–1 was comparable with clinical trial data that found 69.8%/45.7% and 48.0%/27.3% survival at 12/24 months for PD-1/PD-L1 inhibitor-based regimens and PBC, respectively, in the KN189 trial (61) and 70.3%/51.5% survival at 12/24 months for PD-1/PD-L1 inhibitor monotherapy in the KN024 trial (62) with similar results in the IMPOWER110 trial (63). Here, CD274 is linked to primary biliary cholangitis.